Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis
Status:
Completed
Trial end date:
2016-08-23
Target enrollment:
Participant gender:
Summary
This study is an open-label, long-term study for those patients who participated in the prior
proof-of-concept protocol, in which the preliminary efficacy for BYM338 in patients with sIBM
was demonstrated after a single 30 mg/kg i.v. dose of BYM338. This study is designed to
confirm the efficacy, safety and tolerability of BYM338 in sIBM with long-term dosing.
However due to lack of efficacy in patients with sIBM, the study was terminated early.